G'day Gerry,
The company already has patent protection (effectively to 2015). Today's news of the "in-tube" test effectively increases their patent protection out to 2020.
It is FDA and Japan approvals that we are awaiting.
I am unsure whether the company has any intention of listing elsewhere. I can't see any valid reason for doing this. Perhaps to appease the Americans? The company certainly will not need any further cash injections.
